首页> 外文期刊>Sleep medicine >Concomitant use of modafinil and tranylcypromine in a patient with narcolepsy: a case report.
【24h】

Concomitant use of modafinil and tranylcypromine in a patient with narcolepsy: a case report.

机译:发作性睡病患者同时使用莫达非尼和反式环丙胺:一例病例报告。

获取原文
获取原文并翻译 | 示例
       

摘要

This is a case report of a patient with narcolepsy treated simultaneously with modafinil and tranylcypromine. The concurrent use of these two medications is normally contraindicated based on theoretical concerns. To our knowledge this is the first report of the combined use of these two medications in a patient for any reason. This combination of medications was particularly effective in the treatment of the patient's narcoleptic symptoms and was well tolerated, with no evidence of the potential cardiovascular side effects. Due to modafinil's lack of sympathomimetic activity and unique pharmacological profile, it may be well tolerated with monoamine oxidase inhibitor's (MAOI's) in humans with respect to hemodynamic parameters and concerns of hypertensive crisis. Further investigation would help clarify cardiovascular safety issues in using this combined therapy. We believe that with proper informed consent from the patient and careful monitoring, a combination of an MAOI and modafinil may be a viable treatment alternative in refractory cases of narcolepsy.
机译:这是一例发作性睡病患者同时用莫达非尼和反式环丙胺治疗的病例报告。基于理论上的考虑,通常禁止同时使用这两种药物。据我们所知,这是这两种药物由于某种原因在患者中联合使用的首次报道。这种药物组合在治疗患者的麻醉性症状方面特别有效,并且耐受性良好,没有证据表明存在潜在的心血管副作用。由于莫达非尼缺乏拟交感神经活性和独特的药理作用,因此在血液动力学参数和高血压危象方面,单胺氧化酶抑制剂(MAOI's)可以很好地耐受人类。进一步的研究将有助于弄清楚使用这种联合疗法的心血管安全性问题。我们相信,在患者适当知情同意和仔细监测的情况下,在难治性发作性睡病患者中,MAOI和莫达非尼的组合可能是可行的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号